# An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder

> **NCT02473289** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 193 (actual)

## Conditions studied

- Depressive Disorder, Major

## Interventions

- **DRUG:** Sirukumab 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02473289
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-23
- **Primary completion:** 2018-05-22
- **Final completion:** 2018-05-22
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02473289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02473289, "An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02473289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*